CUPERTINO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- In conjunction with
DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2008 financial results
press release, you are invited to listen to the conference call that will be
broadcast live over the Internet on Monday, February 9th, 2009 at 4:30 p.m.
EST (1:30 PST).
A live audio webcast of the presentation will be available by accessing
DURECT's homepage at www.durect.com and clicking "Investor Relations." If you
are unable to participate during the live webcast, the call will be archived
on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY(TM), POSIDUR(TM), ELADUR(TM), and
TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and
injectable depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the US Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
/CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT
PRN Photo Desk, firstname.lastname@example.org
Web Site: www.durect.com